ST Renfu Gains UK Regulatory Approval for Midazolam Injection

Stock News
Aug 20

ST Renfu (600079.SH) has announced that its majority-owned subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd. (referred to as "Yichang Humanwell", in which the company holds an 80% equity stake), has received a marketing authorization approval letter for Midazolam Injection from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The approval covers the use of Midazolam Injection for the following indications: (1) conscious sedation before, during, and after diagnostic or therapeutic procedures, whether or not combined with local anesthesia; (2) premedication before anesthesia induction in adults, anesthesia induction, and use as a sedative in combination with other anesthetics; premedication before anesthesia induction in children; and (3) sedation in intensive care unit (ICU) settings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10